Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis | Zendy

Nina Fokter Dovnik | Zendy; Andraž Dovnik | Zendy; Nina Čas Sikošek | Zendy; Maja Ravnik | Zendy; Darja Arko | Zendy; Iztok Takač | Zendy

Open Access

Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis

Author(s) -

Nina Fokter Dovnik,

Andraž Dovnik,

Nina Čas Sikošek,

Maja Ravnik,

Darja Arko,

Iztok Takač

Publication year - 2016

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000454690

Subject(s) - medicine , trastuzumab , oncology , breast cancer , hazard ratio , proportional hazards model , adjuvant , lymph node , retrospective cohort study , confidence interval , adjuvant therapy , cancer

The natural course of traditionally prognostically unfavorable human epidermal growth factor receptor 2 (HER2)-positive breast cancer has been changed by anti-HER2 therapy. It is not clear whether the prognosis for HER2-positive patients treated with adjuvant trastuzumab differs from that of HER2-negative patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research